These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32737143)

  • 1. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
    Bedrose S; Miller KC; Altameemi L; Ali MS; Nassar S; Garg N; Daher M; Eaton KD; Yorio JT; Daniel DB; Campbell M; Bible KC; Ryder M; Chintakuntlawar AV; Habra MA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
    Al-Toubah T; Schell MJ; Morse B; Haider M; Valone T; Strosberg J
    ESMO Open; 2024 Apr; 9(4):102386. PubMed ID: 38507897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
    Chen TH; Chang PM; Yang MH
    J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
    Makker V; Taylor MH; Aghajanian C; Oaknin A; Mier J; Cohn AL; Romeo M; Bratos R; Brose MS; DiSimone C; Messing M; Stepan DE; Dutcus CE; Wu J; Schmidt EV; Orlowski R; Sachdev P; Shumaker R; Casado Herraez A
    J Clin Oncol; 2020 Sep; 38(26):2981-2992. PubMed ID: 32167863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
    Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
    J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
    Wortmann S; Quinkler M; Ritter C; Kroiss M; Johanssen S; Hahner S; Allolio B; Fassnacht M
    Eur J Endocrinol; 2010 Feb; 162(2):349-56. PubMed ID: 19903796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report.
    Li L; Yu D; Yang J; Zhang F; Zhang D; Lin Z; Zhai M; Wang J; Zhang T; Zhao L
    Cancer Biol Ther; 2024 Dec; 25(1):2338644. PubMed ID: 38650446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
    BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
    Liu Z; Li X; He X; Xu Y; Wang X
    BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review.
    Lei Y; Zhao S; Jiang M
    Front Immunol; 2021; 12():653319. PubMed ID: 34566950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
    Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
    Raj N; Zheng Y; Kelly V; Katz SS; Chou J; Do RKG; Capanu M; Zamarin D; Saltz LB; Ariyan CE; Untch BR; O'Reilly EM; Gopalan A; Berger MF; Olino K; Segal NH; Reidy-Lagunes DL
    J Clin Oncol; 2020 Jan; 38(1):71-80. PubMed ID: 31644329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.